Protalix BioTherapeutics (PLX) Cash from Discontinued Operations (2015 - 2017)

Protalix BioTherapeutics' Cash from Discontinued Operations history runs 3 years deep, the most recent figure standing at 2000.0 for Q3 2017.

• On a quarterly basis, Cash from Discontinued Operations rose 100.68% year-over-year to 2000.0 in Q3 2017; TTM through Sep 2017 was 116000.0, a 97.19% decrease from a year earlier, with the FY2016 full-year figure at 11000.0, down 100.74% from the prior year.
• Cash from Discontinued Operations grew to 2000.0 in Q3 2017 per PLX's latest filing, from 8000.0 in the prior quarter.
• Across five years, Cash from Discontinued Operations topped out at 4138000.0 in Q4 2015 and bottomed at 1406000.0 in Q3 2015.
• The 3-year median for Cash from Discontinued Operations is 131000.0 (2015), against an average of 159100.0.
• Across the five-year window, Cash from Discontinued Operations jumped 164.72% in 2016 and plunged 101.25% in 2017, its largest moves.
• Year by year, Cash from Discontinued Operations stood at 4138000.0 in 2015, then slumped by 107.15% to 296000.0 in 2016, then soared by 100.68% to 2000.0 in 2017.
• Per Business Quant, the three latest PLX Cash from Discontinued Operations figures stand at 2000.0 (Q3 2017), 8000.0 (Q2 2017), and 122000.0 (Q1 2017).